Caption Management’s TherapeuticsMD TXMD Stock Holding History

Caption Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-266	Closed	-$26.4K	–	1085
2019 Q4	$32K	Buy	+266	New	+$38.2K	﹤0.01%	786

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's TXMD Position: Q1 2020 in Review

Caption Management sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 266 shares — an estimated $26.4K sold.

Caption Management first reported a position in TXMD in Q4 2019 and held it in 1 quarter. The position peaked at $32K in Q4 2019. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Caption Management reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Caption Management sold 266 TherapeuticsMD shares in Q1 2020, an estimated $26.4K.
Caption Management first reported a position in TherapeuticsMD in Q4 2019 and held it in 1 quarter.
Caption Management's TherapeuticsMD position peaked at $32K in Q4 2019.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Caption Management's 13F filing for Q1 2020, filed 15 May 2020.